Semaglutide (GLP-1): 20mg
Weight managementDescription
Glp-1 (glucagon-like peptide-1) is an incretin hormone naturally released by the gut after eating. as a receptor agonist, it enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and signals the brain's hypothalamus to reduce appetite — all through binding to glp-1 receptors expressed in the pancreas, brain, gut, and adipose tissue. brain-mediated appetite suppression is now considered the primary driver of its weight loss effects, with preclinical research showing that glp-1 action restricted to the brain alone still produces significant food intake reduction. phase 3 clinical trials with glp-1 agonists have demonstrated mean body weight reductions of approximately 15% over 68 weeks, with approximately 50% of participants achieving 15% or more weight loss. common research side effects include nausea, vomiting, and constipation, particularly during dose titration — which is why starting doses are low and titrated upward gradually. for research and educational purposes only. consult a qualified healthcare professional.
Specifications
| Amount in Vial | 20mg |
|---|---|
| BAC Water | 4ml |
| Amount per Unit | 0.05mg per unit |
| Recommended Dose | titrate up from 250mcg to 2.5mg (5 to 50 units) |
| Frequency | 1x per week |
| Injection Type | Subcutaneous |
| Timing | Same Day Every Week / Starting Dose Is 250 MCG |
Dose Calculator
Based on 0.05mg per unit (100-unit insulin syringe)
Quick Reference
Reconstitution
Vial size: 20mg
Add BAC water: 4ml
Concentration: 0.05mg per unit
For research and educational use only.
This page provides research dosing information only. Not intended as medical advice. Consult a qualified professional before any use.